Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 65-73
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.65
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.65
Mirabegron, a novel, non-antimuscarinic drug for the overactive bladder: An up-to-dated review
Emilio Sacco, Riccardo Bientinesi, Urologic Clinic, “Agostino Gemelli” Hospital, Catholic University Medical School of Rome, 00168 Rome, Italy
Author contributions: Sacco E wrote the paper; Bientinesi R contributed to literature review and drafting the manuscript.
Correspondence to: Emilio Sacco, MD, PhD, Urologic Clinic, “Agostino Gemelli” Hospital, Catholic University Medical School of Rome, Largo F Vito 1, 00168 Rome, Italy. emilio.sacco@gmail.com
Telephone: +39-6-30155290 Fax: +39-6-30155975
Received: May 14, 2013
Revised: June 29, 2013
Accepted: July 4, 2013
Published online: November 10, 2013
Revised: June 29, 2013
Accepted: July 4, 2013
Published online: November 10, 2013
Core Tip
Core tip: Mirabegron is a first-in-class, potent β3-adrenoceptors agonist that has been proven effective in the treatment of overactive bladder (OAB) based on multiple randomized multinational trials. The safety-tolerability profile of treatment with mirabegron has been extensively studied. The placebo-like incidence of classic adverse effects caused by antimuscarinics should improve long-term adherence to treatment with this new drug. Mirabegron can be an alternative in patients with contraindications to antimuscarinics or that discontinued previous antimuscarinic therapy. An updated review of the rationale of β3-agonism for OAB treatment and evidence of efficacy and safety of mirabegron is presented.